Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Referanser til leverkreft

  1. Cancer in Norway 2015, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
  2. Mazzaferro V, Regalia E, Dolci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrohosis. New Engl J Med. 1995 334 (11) 693–699  
  3. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A et al. Phase III randomized controlled trial comparing the survival of patients with resectable hepatocellular carcinoma treats with nolatrexed doxorubicin. J Clin Oncol 2007;25: 3069–75
  4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 2008; 359: 378–90.
  5. Abou-Alfa GK et al. Final results from phase II randomized double-blind study of sorafineb plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. 2008 Gastrointestinal Cancers Symposium. Abstr no: 128
  6. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35; 1164–71
  7. Llovet JM , M Real , X Montaña , R Planas , S Coll , J Aponte et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002, 359, 1734–39.
  8. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma. IJRBP 2003, 55, 329–336.
  9. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients Clin Can Res 2005, 11, 3799–805

Prosedyrer i Oncolex kan ikke erstatte faglig veiledning fra kvalifisert veileder. Den som følger prosedyrene har et selvstendig ansvar for at det foreligger nødvendig godkjenning, lisens eller autorisasjon.
Oslo universitetssykehus HF © 2016